Transforming the way diseases are detected, tracked, treated, and understood.
No new events at this time.
#GlympseBio is powered by our diverse team, innovative ideas, and disruptive technology. Our values guide us in our mission to enhance our understanding of human disease.
Learn more about our values and leadership: https://glympsebio.com/about-us/
Our #biosensors are designed to measure the disease trajectory of #NASH and other fibrotic diseases as a noninvasive alternative to biopsy.
Learn more about #GlympseBio technology: https://glympsebio.com/technology/
Recently #GlympseBio CEO Dr. Caroline Loew sat down with @BioPharmaMike on @DRGInsights’ “Conversations in Healthcare” series to discuss our technology in development and response to #COVID19.
Watch now: https://decisionresourcesgroup.com/downloads/glympse-bio-oversubscribed-series-b-funding-amidst-pandemic/
Early detection of #NAFLD is key to preventing the onset of #NASH. #GlympseBio is committed the development of our repeatable, noninvasive disease detection platform to better understand disease progression.
Learn more from @liverUSA: https://liverfoundation.org/wp-content/uploads/2018/04/ALF-NAFLD-NASH-Infographic.pdf